Skip to main content

Advertisement

Table 2 Outcomes and efficacy of mobilization in 39 patients with high-risk non-Hodgkin’s lymphoma

From: Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma

Parameter All patients (n = 39) R-CHOP (n = 14) CHOP (n = 25) P value
Time from mobilization chemotherapy to rhG-CSF support (days)a 9 (6–15) 12.5 (9–15) 12 (6–15) 0.082
Duration of rhG-CSF support (days)a 5 (3–10) 5 (3–9) 5 (4–10) 0.343
Time from mobilization chemotherapy to apheresis (days)a 16 (12–20) 16.5 (15–18) 16 (12–20) 0.032
Percentage of CD34+ cells in peripheral blood on the first day of apheresis (%)a 2.43 (0.36–7.50) 1.35 (0.36–3.41) 3.14 (1.14–7.50) 0.002
Peripheral blood WBC count on the first day of apheresis (×109/L)a 14.30 (3.55–43.20) 10.35 (3.55–43.20) 17.15 (5.56–41.60) 0.031
Number of apheresis proceduresa 1 (1–3) 1 (1–2) 1 (1–3) 0.593
CD34+ cells collected on day 1 (×106 cells/kg body weight)a 5.79 (0.40–18.50) 4.83 (1.03–8.11) 7.07 (0.40–18.50) 0.016
CD34+ cells collected in total (×106 cells/kg body weight)a 7.01 (1.49–28.39) 5.01 (1.49–13.40) 8.25 (1.61–28.39) 0.005
CD34+ cells collected per apheresis (×106 cells/kg body weight)a 5.97 (0.75–18.50) 4.83 (0.75–8.11) 7.31 (0.81–18.50) 0.014
Optimal mobilization of CD34+ cell collection [cases (%)] 27 (69.2) 7 (50.0) 20 (80.0) 0.075
Successful mobilization of CD34+ cells [cases (%)] 37 (94.5) 13 (92.9) 24 (96.0) 1.000
  1. rhG-CSF recombinant human granulocyte colony-stimulating factor, WBC white blood cell. Other abbreviations as in Table 1
  2. aThe values are presented as median followed by range in parentheses; other values are presented as the number of patients followed by percentages in parentheses